Transwell assays also showed that the invasion ability of CML cells was significantly reduced by treatment with either miR-181a mimic or PPFIA1 siRNA (Figure 2B). This evidence concerns the gene PPFIA1 and chronic myelogenous leukemia, BCR-ABL1 positive.